Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection